ArticleERJ open research2026
Transitions to and reversion from a persistent frequent-exacerbator state in COPD.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preventing acute exacerbations in COPD (AECOPDs) is key in striving for disease stability. To investigate the differential impact of risk factors across AECOPD phenotypes, we identified baseline health determinants and comorbidities associated with transitions from non-exacerbator (NE) to persistent frequent-exacerbator (FE) and reversion. Methods: Patients ≥45 years with ≥3 months treatment for obstructive airway diseases or hospital-labelled COPD without (concomitant) asthma were identified in Belgian nationwide data between January 2017-February 2018. Factors associated with disease worsening (transitioning from NE to persistent FE), reversion (from FE to stable NE) or transition to death were investigated using multinomial logistic regression. Results: Among 183 762 patients (mean age 68.6 years, 48.0% female), 11.5% (21 072) never experienced AECOPDs and 11.6% (21 375) exacerbated frequently in each of three consecutive years. Among 56 933 NE at baseline (31.0%), 4.1% transitioned to persistent FE, whereas among 80 502 FE (43.8%), 7.3% reversed to stable NE. Transitions from NE towards persistent FE were associated with having lung cancer (adjusted odds ratio (aOR) 3.67, 95% CI 2.33-5.78), being an ever-smoker (aOR 2.09, 95% CI 1.94-2.43) or having neuropsychiatric or musculoskeletal comorbidity. Overuse of short-acting bronchodilators (aOR 0.57, 95% CI 0.46-0.49), ever-smoking or having overuse of maintenance therapy were factors most strongly associated with lower odds of reversion. Cardiovascular comorbidities were significantly associated with increased mortality odds, but not with disease worsening. Conclusions: The results of this cohort study support addressing smoking and inhaler overuse to promote reversion to stable NE, while managing lung cancer and neuropsychiatric or musculoskeletal comorbidities to reduce worsening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.